Switching from Dulaglutide to Tirzepatide Improves Blood Sugar, Weight, and Liver Function

Switching from dulaglutide to tirzepatide produced average reductions of 1.2% in HbA1c and 3.6 kg in body weight at 6 months. Liver enzymes (AST, ALT, GGT) significantly decreased. HbA1c reduction correlated with higher baseline HbA1c, while weight loss was baseline-independent. Fibrosis-4 index trended toward improvement in those with higher baseline values.

Single-center retrospective study in Japan. 40 patients with type 2 diabetes who switched from dulaglutide to tirzepatide were analyzed at 3 and 6 months post-switch. Outcomes: HbA1c, body weight, AST, ALT, GGT, and fibrosis-4 index.

Many patients on GLP-1 monotherapy don't achieve optimal control. This study provides real-world evidence that switching to a dual-pathway peptide (tirzepatide) can deliver additional metabolic and liver benefits, which is clinically relevant as physicians decide when and how to escalate therapy.

This supports the growing evidence that dual GIP/GLP-1 peptide agonism (tirzepatide) outperforms GLP-1-only agonists. The liver improvements are particularly notable given the rising prevalence of metabolic liver disease in diabetic patients.

Very small sample (40 patients). Single-center retrospective design. No control group. 6-month follow-up may miss longer-term effects. Japanese population may not represent other ethnic groups. Specific tirzepatide doses not detailed in abstract.